Non Invasive Prenatal Diagnosis (NIPD) on circulating fetal trophoblastic cells (CFTC) for Triplet Repeat Diseases
The main objective of DIACCIMEX is to develop and validate an analytical and clinical Non-Invasive Prenatal Diagnosis (NIPD) test for triplet repeat diseases by isolated circulating fetal trophoblastic cells (CFTC) analysis from maternal blood, searching for the familial mutation in families at risk of having one of the following triplet repeat diseases: Huntington’s disease, Steinert Myotonic dystrophy, Fragile X syndrome, spinocerebellar ataxia (SCA) 1, 2 and 3.
Completion Date: 1 April, 2020
18 Years and older (Adult, Older Adult)
Female
Yes
TRIAL SITE:
CHU Bordeaux
Address: Bordeaux, France
TRIAL SITE:
CHU Montpellier
Address: Montpellier, France
TRIAL SITE:
CHU Nice
Address: Nice, France
TRIAL SITE:
CHU Nîmes
Address: Nîmes, France
TRIAL SITE:
CHU Rennes
Address: Rennes, France
TRIAL SITE:
CHU Saint Brieuc
Address: Saint Brieuc, France
TRIAL SITE:
CHU Strasbourg
Address: Schiltigheim, France
TRIAL SITE:
CHU Toulouse
Address: Toulouse, France
a single-letter spelling difference in a gene. SNPs, pronounced ‘snips’, are common and most don’t change the function of the gene.
You do not know if you carry the genetic mutation for HD gene
A standardized rating scale for function in HD, used to assess capacity to work, handle finances, perform domestic chores and self-care tasks.
Scores range from 0 to 13, with higher scores indicating better functional capacity.
means that neither the participant nor the clinical trial doctor can choose or know the group the participant is in until the trial is over. This approach helps to prevent bias.
A trial in which the patient and doctor know what drug is being used. Open label trials are susceptible to bias through placebo effects.
a technique that aims to treat or prevent diseases by modifying a person’s genes. It involves introducing, removing, or changing genetic material (DNA or RNA) within a patient’s cells.
A standardized neurological examination that aims to provide a uniform assessment of the clinical features of HD
The stretch of DNA at the beginning of the HD gene, which contains the sequence CAG repeated many times, and is abnormally long in people who will develop HD
the opposite of ‘mutant’. Wild-type huntingtin, for example, is the ‘normal’, ‘healthy’ protein
How well a person can handle a treatment without having serious or uncomfortable side effects.
Part of the brain that coordinates multiple aspects of cognition, including both motor and action planning, decision-making, motivation, reinforcement, and reward system.
A type of allocation strategy in which participants are assigned to the arms of a clinical trial by chance.
a radioactive substance that binds to a specific target in the body, allowing visualization of that target’s distribution and activity
Protein builds, maintains, and replaces the tissues in your body. The building blocks of life.
Prior to onset or diagnosis of movement symptoms.
A placebo is a dummy medicine containing no active ingredients. The placebo effect is a psychological effect that causes people to feel better even if they’re taking a pill that doesn’t work.
The movement of drugs through the body
The body’s biological response to drugs
Positron emission tomography which produces detailed 3-dimensional images of the inside of the body.
Brain cells that store and transmit information
Magentic resonance imaging: A technique using powerful magnetic fields to produce detailed images and visualizes the structure of organs, tissues, and bones
Mutant huntingtin protein. The protein produced by the faulty HD gene.
after HD diagnosis, or when symptoms are already showing
A study where each participant is looked at several times over a time period – unlike a cross-sectional study, where each participant is looked at only once
one abbreviation for the gene that causes Huntington’s disease. The same gene is also called HD and IT-15
functional MRI:As with MRI, a technique using powerful magnetic fields but focusing on brain function by measuring and mapping changes in blood flow, revealing which areas of the brain are active during specific tasks or cognitive processes
A clear fluid produced by the brain, which surrounds and supports the brain and spinal cord.
A measure of whether a treatment works or not
A type of gene silencing treatment in which specially designed DNA molecules are used to switch off a gene
a test of any kind – including blood tests, thinking tests and brain scans – that can measure or predict the progression of a disease like HD. Biomarkers may make clinical trials of new drugs quicker and more reliable
Brain-derived neurotrophic factor: a growth factor that may be able to protect neurons in HD.
one of the two copies of a gene
Liquid component of the blood.
The basic unit of heredity passed from parent to child. Genes are made up of sequences of DNA and are arranged, one after another, at specific locations on chromosomes in the nucleus of cells.
Each phase has a specific goal and involves a different number of participants. Generally, there are 4 phases (I-IV), with Phase I focusing on safety and dosage, Phase II on efficacy and side effects, Phase III on comparing the new treatment with standard treatments, and Phase IV on long-term safety monitoring.
